937174-75-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-tert-butyl 3-((2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methylbut-1-ynyl)-1H-imidazo[4,5-c]pyridin-7-yloxy)methyl)piperidine-1-carboxylate is used as a potential pharmaceutical compound for its unique structure and functional groups that may allow for specific biological activities or interactions within living organisms.
Used in Research and Development:
In the field of research and development, (S)-tert-butyl 3-((2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methylbut-1-ynyl)-1H-imidazo[4,5-c]pyridin-7-yloxy)methyl)piperidine-1-carboxylate serves as a valuable compound for studying its properties, interactions, and potential applications in various scientific and medical fields. Its complex structure and functional groups make it an interesting subject for further investigation and experimentation.

Upstream product

• 937174-74-8 1,1-dimethylethyl (3S)-3-({[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy}methyl)-1-piperidinecarboxylate 
• 115-19-5 2-methyl-but-3-yn-2-ol 
• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 158406-99-6 1,1-dimethylethyl (3S)-3-(bromomethyl)-1-piperidinecarboxylate 
• 842149-46-6 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ol 
• 842144-04-1 N-[5-romo-2-chloro-4-(ethylamino)-3-pyridinyl]-2-cyanoacetamide 
• 842144-05-2 (7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile 
• 842144-03-0 5-bromo-2-chloro-N₄-ethylpyridine-3,4-diamine 
• 607371-01-7 ethyl-(3-bromo-5-nitropyridin-4-yl)amine 

Downstream Products

• 937174-76-0 GSK₆₉₀₆₉₃ 

Relevant academic research and scientific papers

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3- piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3β. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.

METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY

Invented is the use of 1 H-imidazo[4,5-c]pyridin-2-yl compounds in the treatment of specified cancers.